STOCK TITAN

Sana Biotechnology, Inc. - SANA STOCK NEWS

Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.

Sana Biotechnology, Inc. (SANA) is a leading developer of engineered cell therapies targeting complex diseases through innovative gene editing and immune evasion technologies. This resource provides centralized access to official press releases, clinical trial milestones, and strategic updates from the company.

Investors and industry observers will find timely updates on SANA's hypoimmune (HIP) platform progress, allogeneic CAR T-cell therapy developments, and advancements in diabetes/autoimmune disease research. The curated news collection includes regulatory filings, partnership announcements, and financial results essential for tracking this biotechnology innovator.

Key content categories include clinical trial phases, scientific publications, manufacturing expansions, and intellectual property developments. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.

Bookmark this page for streamlined monitoring of SANA's progress in creating off-the-shelf cellular medicines. Check back regularly for verified updates on their pipeline targeting oncology, diabetes, and central nervous system disorders.

Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) has received FDA clearance to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, particularly those who have received prior CD19-directed CAR T therapy. The company aims to address the significant unmet need for patients who have failed CD19-directed CAR T therapy by introducing SC262, which has shown durable complete responses in a substantial number of patients in the relapse setting. Sana has received three IND regulatory clearances and supported the authorization of an investigator-sponsored CTA to begin new studies utilizing their hypoimmune platform in seven different indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes. The company is expected to disclose initial proof of concept data for SC262 in 2024, presenting data from all of their studies this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will include a business overview and update by Steve Harr, Sana’s President and CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
-
Rhea-AI Summary
Sana Biotechnology, a company listed as NASDAQ: SANA, announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP) technology at the 65th American Society of Hematology (ASH) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
Rhea-AI Summary
Sana Biotechnology, a company focused on engineered cells, announced the publication in Blood of initial clinical data from the ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL). ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (SANA) will present at two investor conferences in November and December, featuring a business overview and update. The company will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, and at the JMP Securities Hematology and Oncology Summit on December 6, 2023. Webcasts will be accessible on Sana's Investor Relations page with replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
conferences
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) and Uppsala University Hospital in Sweden have announced the authorization of Uppsala University’s Clinical Trial Application (CTA) to initiate a first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes. The goal is to provide proof of concept for transplanting functional islet cells without immunosuppression. The study will focus on safety, cell survival, immune evasion, and C-peptide production. Insights from this study may inform the development of Sana’s SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) receives FDA clearance for Phase 1 trial of SC291, a CAR T cell therapy for multiple B-cell mediated autoimmune diseases. Initial clinical data expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) reported financial results and business highlights for the third quarter 2023. The company is focusing on developing hypoimmune technology, with potential data from four clinical settings in 2023 and 2024. They are enrolling patients for Phase 1 ARDENT trial investigating SC291 in refractory B-cell malignancies, submitting CTA for IST evaluating HIP-modified primary islet cells in type 1 diabetes patients, and expecting proof of concept data for SC291 in multiple B-cell-mediated autoimmune diseases in 2024. Additionally, they are presenting multiple abstracts at the 2023 ASH Annual Meeting and have a cash position of $268.6 million expected to last into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting. The presentations will cover topics such as the treatment of large B cell lymphoma patients, genetic engineering of human hematopoietic stem progenitor cells, and the development of a novel CAR for multiple myeloma patients. The presentations will take place from December 9-12, 2023, in San Diego, CA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
Rhea-AI Summary
Sana Biotechnology announces increased focus on ex vivo cell therapy platform and IND submission for SC291 in autoimmune diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.95%
Tags
none
Sana Biotechnology, Inc.

Nasdaq:SANA

SANA Rankings

SANA Stock Data

371.29M
205.00M
8.58%
93.7%
18.81%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SEATTLE